Drug Trial Radar · NCT00549770
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
Last checked: Nov 19, 2026Latest source record: Aug 25, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,334
Actual
Start
Sep 2007
Primary completion
Jul 2008
Study completion Jul 2008
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 26, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was a dose-ranging efficiacy study in patients with essential hypertension to assess the blood pressure lowering effect, and safety of LCZ696 compared to valsartan and placebo. The study will also evaluate the efficacy and safety of AHU377 as compared to placebo.
Conditions
- Hypertension
Interventions
LCZ696Drug
ValsartanDrug
AHU377Drug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)Time frame: baseline, week 8
Locations
182 sites in 18 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Birmingham, Alabama
Novartis Investigative Site
Muscle Shoals, Alabama
Novartis Investigative Site
Chandler, Arizona
Novartis Investigative Site
Buena Park, California
Novartis Investigative Site
Fair Oaks, California
Novartis Investigative Site
Long Beach, California
Novartis Investigative Site
Los Angeles, California
Novartis Investigative Site
Orangevale, California
Novartis Investigative Site
Santa Ana, California
Novartis Investigative Site
Stockton, California
Novartis Investigative Site
Tustin, California
Novartis Investigative Site
Jacksonville, Florida
Novartis Investigative Site
Pembroke Pines, Florida
Novartis Investigative Site
Pembroke Pines, Florida
Novartis Investigative Site
Pensacola, Florida
Novartis Investigative Site
Augusta, Georgia
Novartis Investigative Site
Chicago, Illinois
Novartis Investigative Site
Chicago, Illinois
Novartis Investigative Site
Peoria, Illinois
Novartis Investigative Site
Baton Rouge, Louisiana
Novartis Investigative Site
Metairie, Louisiana
Novartis Investigative Site
Chelsea, Michigan
Novartis Investigative Site
Royal Oak, Michigan
Novartis Investigative Site
Brooklyn Center, Minnesota
Novartis Investigative Site
City of Saint Peters, Missouri
Novartis Investigative Site
Toms River, New Jersey
Novartis Investigative Site
Trenton, New Jersey
Novartis Investigative Site
Cincinnati, Ohio
Novartis Investigative Site
Cincinnati, Ohio
Novartis Investigative Site
Oklahoma City, Oklahoma
Novartis Investigative Site
Simpsonville, South Carolina
Novartis Investigative Site
Dallas, Texas
Novartis Investigative Site
Houston, Texas
Novartis Investigative Site
Houston, Texas
Novartis Investigative Site
Houston, Texas
Novartis Investigative Site
Lake Jackson, Texas
Novartis Investigative Site
Richmond, Virginia
Novartis Investigative Site
Charleston, West Virginia
Novartis Investigative Site
Caba, Buenos Aires, Argentina
Novartis Investigative Site
Caba, Buenos Aires, Argentina
Showing 40 of 182 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.